Using α-ketoglutarate to treat hypertension

The Effects of α-ketoglutarate on Blood Pressure and Endothelial Function in Hypertensive Patients

This study is testing if taking α-ketoglutarate can help people with high blood pressure feel better and improve their blood vessel health.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 30 (estimated)
• Ages: 18 Years to 65 Years
• Sex: All
• Sponsor: First Affiliated Hospital, Sun Yat-Sen University (other)
• Locations: 1 site (Guangxi, Nanning)
• Trial ID: NCT06445244 on ClinicalTrials.gov

What this trial studies

This study investigates the effects of α-ketoglutarate supplementation on patients with primary hypertension and vascular dysfunction. Participants will receive 1000mg capsules of α-ketoglutarate along with lifestyle modification guidance. The aim is to reduce blood pressure and improve endothelial function, potentially reversing the pathological changes associated with hypertension. The study targets individuals aged 18 to 65 who meet specific blood pressure criteria and have not used certain medications recently.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 65 with primary hypertension and vascular dysfunction.

Not a fit: Patients with secondary hypertension or those currently using medications that affect blood pressure will not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a novel approach to managing hypertension and preventing cardiovascular diseases.

How similar studies have performed: While the approach of using α-ketoglutarate is relatively novel, recent clinical trials have shown promising results in related areas.

Eligibility criteria

Inclusion Criteria:

1、 Primary hypertension (office blood pressure: systolic blood pressure 130～159 mmHg and/or diastolic blood pressure 80～99 mmHg, which meets the diagnostic criteria of hypertension class 1 of 2018AHA hypertension guidelines) and accompanied by vascular dysfunction (FMD\<5%); 2、 Age between 18 and 65 years old; 3, Not using any drugs and dietary supplements that affect blood pressure and vascular endothelial function in the last 3 months, mainly including antihypertensive, lipid-lowering, hypoglycemic drugs and natural plant extract antioxidants; 4、 Voluntarily sign the informed consent form after fully understanding the purpose and process of the study, disease characteristics, drug effects, methods of relevant examinations, and potential risks/benefits of the study.

Exclusion Criteria:

1. Presence of secondary hypertension (those who have been diagnosed with secondary hypertension in the past and have not been definitively cured, and if secondary hypertension is suspected, a complete examination is required to exclude common secondary hypertension, including renal hypertension (renal parenchymal lesions, renal artery stenosis), primary aldosteronism, Cushing's syndrome, pheochromocytoma, aortic constriction, and severe obstructive sleep apnea);
2. Acute myocardial infarction within the past 6 months;
3. recent history of stroke (within 6 months); 4, Dilated heart disease, hypertrophic cardiomyopathy, rheumatic heart disease, congenital heart disease, severe heart valve disease (severe valve stenosis and or regurgitation);

5\. patients with a combination of serious physical illnesses, such as cancer; 6, Severe hepatic or renal dysfunction (ALT and or AST) ≥ 3 times the upper limit of normal, or dialysis end-stage renal disease or eGFR \< 30 ml/min/1.73 m2, or serum creatinine \> 2.5 mg/dL \[\> 221 μmol/L\]); 7. Symptomatic heart failure or reduced left ventricular ejection fraction (\<40%) within the past 6 months; 8. History of hypersensitivity to the study drug or to its components after administration; 9. Participating in other clinical studies; 10. Patients with mental illness who are unable to cooperate; 11, Pregnant, lactating or expectant mothers;

Where this trial is running

Guangxi, Nanning

• Wenhao Xia — Guangxi, Nanning, China (RECRUITING)

Study contacts

• Study coordinator: Xia Wenhao, MD, PhD

Conditions: Hypertension